Description
A nanomolar potent, selective, and orally bioavailable glycine transporter type-1 (GlyT1) inhibitor for the treatment of negative symptoms associated with schizophrenia; dose-dependently increases cerebrospinal fluid (CSF) glycine concentration in rats and humans. Schizophrenia Phase 2 Discontinued